WeTrials
Recruiting

A Phase Ia/Ib, Open Label, Multi-center, Non-randomized Dose Escalation and Dose Expansion Study of RSC-1255 Alone or in Combination With Hydroxychloroquine in Patients With Advanced Solid Tumor Malignancies

What is this study?

This study is testing a new experimental medicine called RSC-1255, either by itself or combined with another drug, to see how safe it is and how well it works. It is designed for adults with advanced solid tumor cancers like lung, colon, pancreatic, or certain brain tumors that have not responded to standard treatments.

Who can participate?

You might be able to join if you have an advanced cancer with a specific genetic change called a RAS mutation, and standard treatments have stopped working or you could not tolerate them. Participants must also be free of other serious medical conditions like major heart or liver issues.

What will happen?

You will receive the study drug, RSC-1255, while doctors carefully monitor your health and safety. The first part of the study helps figure out the best dose, and the second part tests that dose in more patients.

Where and when?

This study is currently recruiting participants at multiple locations including Los Angeles, California, Denver, Colorado, and Nashville, Tennessee.

Key Points
  • 1Testing a new cancer drug called RSC-1255 for advanced solid tumors
  • 2Open to adults whose standard cancer treatments have not worked
  • 3Currently actively recruiting patients at multiple US locations

No related links yet

Seen this study covered in the news, or found a page that explains it well? Send it over and we'll review it.

Suggest a link
Conditions Studied
This study is investigating treatments for the following conditions
Advanced Malignant Solid NeoplasmRAS MutationLung CancerColon CancerGlioblastomaPancreatic Cancer

This summary was generated using AI and may not capture all details. Always consult with a healthcare professional for medical advice.